CD37 and B-cell non-Hodgkin lymphoma: DuoHexaBody-CD37 induces not only effective CDC against B cell lymphoma cell lines and primary CLL samples but also can induce efficient ADCC and antibody-dependent cellular phagocytosis (ADCP) in vitro by engaging FcγRs.